Identifying new treatment targets for childhood brain tumors
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
This study is trying to find new ways to treat a rare brain tumor in kids by looking at genetic markers that could make them respond better to a type of cancer drug used for breast cancer.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 0 Years to 18 Years |
| Sex | All |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Roma, ROMA) |
| Trial ID | NCT06959979 on ClinicalTrials.gov |
What this trial studies
This project focuses on medulloblastoma, a rare pediatric brain tumor, and aims to identify genetic markers that influence sensitivity to CDK4/6 inhibitors, which are currently used in breast cancer treatment. By utilizing high-throughput molecular biology techniques, the study will analyze the genetic and transcriptomic profiles of medulloblastoma to understand how these factors contribute to treatment resistance. The goal is to improve therapeutic strategies for children with this aggressive cancer by overcoming the limitations of existing treatments.
Who should consider this trial
Good fit: Ideal candidates for this study are children diagnosed with medulloblastoma who have undergone surgical treatment.
Not a fit: Patients with medulloblastoma who are not eligible for surgical intervention or those with other concurrent severe health conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective and targeted therapies for children with medulloblastoma, reducing neurotoxicity and improving long-term outcomes.
How similar studies have performed: While CDK4/6 inhibitors have shown promise in other cancers, this specific application in medulloblastoma is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients affected by Medulloblastoma operated on at the Pediatric Neurosurgery Unit during their pediatric age will be elected to take part to the study
Where this trial is running
Roma, ROMA
- Fondazione Policlinico Gemelli Irccs — Roma, Roma, Italy (Recruiting)
Study contacts
- Study coordinator: Gianpiero Tamburrini, Md
- Email: gianpiero.tamburrini@unicatt.it
- Phone: 3349468776
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.